|
Prognostic significance of ISG15 and CD3 in gastric cancer: Implications for immune regulation and radiosensitivity
|
Y. Huang   , H.H. Liu , Y. Liang , X.Z. Xu , Z.H. Che , Y.Z. Lin , X.Q. Yu , X. Li , J.Y. Liang , T. Feng |
| Department of Nephrology, The People’s Hospital of Wuzhou, Wuzhou, 543001, Guangxi, China , ArthEynolds6017@hotmail.com |
|
|
Abstract: (315 Views) |
Background: The ISG15 and CD3 play roles in immune regulation and cancer biology, but their prognostic and therapeutic significance in gastric cancer (GC) remains unclear. Materials and Methods: ISG15 expression was evaluated using TCGA and GTEx datasets across various cancers by enrichment and immune infiltration analyses. Immunohistochemistry was performed to assess ISG15 and CD3 expression and their associations with clinicopathological features, prognosis, and correlation with each other on 103 GC specimens. Results: ISG15 was overexpressed in multiple cancers, including GC, and correlated with immune cell infiltration. In the clinical cohort, ISG15 was highly expressed in 68.93% of cases, while CD3 was low in 89.32%. High ISG15 expression correlated with prolonged APTT, whereas high CD3 expression was associated with HER-2 mutation, elevated CA-125 and PCT, and reduced Hb and TC, all indicators of poor prognosis. Both ISG15 and CD3 expression correlated with shorter progression-free survival. A significant positive correlation between ISG15 and CD3 expression was observed. Conclusion: Elevated ISG15 and CD3 predict adverse clinicopathological features and prognosis in GC. Given their roles in immune regulation and DNA damage responses, ISG15 and CD3 may also serve as biomarkers of radiosensitivity, radiotherapy and combined radio-immunotherapy strategies. |
|
| Keywords: Gastric cancer, ISG15 protein, CD3 antigens, radiosensitivity, tumour microenvironment, prognosis. |
|
|
Full-Text [PDF 1171 kb]
(81 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, et al. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3): 209-249. [ DOI:10.3322/caac.21660] 2. Fan X, Qin X, Zhang Y, Li Z, Zhou T, et al. (2021) Screening for gastric cancer in China: advances, challenges and visions. Chinese J Cancer Research, 33(2): 168. [ DOI:10.21147/j.issn.1000-9604.2021.02.05] 3. Yang L, Ying X, Liu S, Lyu G, Xu Z, et al. (2020) Gastric cancer: Epidemiology, risk factors and prevention strategies. Chinese J Cancer Research, 32(6): 695. [ DOI:10.21147/j.issn.1000-9604.2020.06.03] 4. Kusano C, Ishibashi F, Ichita C, Gotoda T (2026) Current status of gastric cancer screening and future perspectives. DEN Open, 6(1): e70148. [ DOI:10.1002/deo2.70148] 5. Cheema AK, Li Y, Ventimiglia M, Kowalczyk, K, et al. (2023) Radiotherapy induces innate immune responses in patients treated for prostate cancers. Clinical Cancer Research, 29(5): 921-929. [ DOI:10.1158/1078-0432.CCR-22-2340] 6. Wardlaw CP and Petrini JH (2023) ISG15: A link between innate immune signaling, DNA replication, and genome stability. Bioessays, 45(7): 2300042. [ DOI:10.1002/bies.202300042] 7. Wardlaw CP and Petrini JH (2022) ISG15 conjugation to proteins on nascent DNA mitigates DNA replication stress. Nature communications, 13(1): 5971. [ DOI:10.1038/s41467-022-33535-y] 8. Huo Y, Zong Z, Wang Q, Zhang Z, Deng H (2017) ISG15 silencing increases cisplatin resistance via activating p53-mediated cell DNA repair. Oncotarget, 8(64): 107452. [ DOI:10.18632/oncotarget.22488] 9. Dai YH, Wang YF, Shen PC, Lo CH, Yang JF, et al. (2021) Radiosensitivity index emerges as a potential biomarker for combined radiotherapy and immunotherapy. NPJ Genomic Medicine, 6(1): 40. [ DOI:10.1038/s41525-021-00200-0] 10. Ratnayake G, Reinwald S, Edwards J, Wong N, et al. (2022) Blood T-cell profiling in metastatic melanoma patients as a marker for response to immune checkpoint inhibitors combined with radiotherapy. Radiotherapy and Oncology, 173: 299-305. [ DOI:10.1016/j.radonc.2022.06.016] 11. Cao M, Cabrera R, Xu Y, Liu C, Nelson D (2011) Different radiosensitivity of CD4+ CD25+ regulatory T cells and effector T cells to low dose gamma irradiation in vitro. Int J Radiation Biology, 87(1): 71-80. [ DOI:10.3109/09553002.2010.518208] 12. Paganetti H (2023) A review on lymphocyte radiosensitivity and its impact on radiotherapy. Frontiers in Oncology, 13: 1201500. [ DOI:10.3389/fonc.2023.1201500] 13. Chen HY, Xu L, Li LF, Liu XX, Gao JX, et al. (2018) Inhibiting the CD8+ T cell infiltration in the tumor microenvironment after radiotherapy is an important mechanism of radioresistance. Scientific Reports, 8(1), 1-10. [ DOI:10.1038/s41598-018-30417-6] 14. Liu J, Li J, Luo F, Wu S, Li B, Liu K (2023) The predictive value of CD3+/CD8+ lymphocyte infiltration and PD-L1 expression in colorectal cancer. Current Oncology, 30(11): 9647-9659. [ DOI:10.3390/curroncol30110699] 15. Zsiros E, Duttagupta P, Dangaj D, Li H, et al. (2015) The ovarian cancer chemokine landscape is conducive to homing of vaccine-primed and CD3/CD28-costimulated T cells prepared for adoptive therapy. Clinical Cancer Research, 21(12): 2840-2850. [ DOI:10.1158/1078-0432.CCR-14-2777] 16. Tsiatas M, Kalogeras KT, Manousou K, Wirtz RM, et al. (2018) Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapy. Cancer Medicine, 7(10): 5066-5082. [ DOI:10.1002/cam4.1730] 17. Giampieri R, Maccaroni E, Mandolesi A, Del Prete M, Andrikou K, et al. (2017) Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. Gastric Cancer, 20(1): 156-163. [ DOI:10.1007/s10120-016-0594-4] 18. Hänzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics, 14(1): 7. [ DOI:10.1186/1471-2105-14-7] 19. Andersen JB, Aaboe M, Borden EC, Goloubeva OG, et al. (2006) Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. British J Cancer, 94(10): 1465-1471. [ DOI:10.1038/sj.bjc.6603099] 20. Uppal A, Dehal A, Chang SC, Barrak D, et al. (2020) The immune microenvironment impacts survival in western patients with gastric adenocarcinoma. Journal of Gastrointestinal Surgery, 24(1): 28-38. [ DOI:10.1007/s11605-019-04403-w] 21. Tas F, Ciftci R, Kilic L, Serilmez M, Karabulut S, Duranyildiz D (2013). Clinical and prognostic significance of coagulation assays in gastric cancer. Journal of Gastrointestinal Cancer, 44(3): 285-292. [ DOI:10.1007/s12029-013-9490-x] 22. Zhang L, Ye J, Luo Q, Kuang M, et al. (2020) Prediction of poor outcomes in patients with colorectal cancer: Elevated preoperative prothrombin time (PT) and activated partial thromboplastin time (APTT). Cancer Management and Research, 5373-5384. [ DOI:10.2147/CMAR.S246695] 23. Lim SC, Parajuli KR, Duong HQ, Choi JE, Han SI (2014) Cholesterol induces autophagic and apoptotic death in gastric carcinoma cells. Int J Oncology, 44(3): 805-811. [ DOI:10.3892/ijo.2014.2246] 24. Gou M, Zhang Y, Liu T, Qu T, et al. (2021) The prognostic value of pre-treatment haemoglobin (Hb) in patients with advanced or metastatic gastric cancer treated with immunotherapy. Frontiers in Oncology, 11: 655716. [ DOI:10.3389/fonc.2021.655716] 25. Huang Q, Zheng X, Jiao Y, Lei Y, et al. (2021) A distinct clinicopathological feature and prognosis of young gastric cancer patients aged≤ 45 years old. Frontiers in Oncology, 11: 674224. [ DOI:10.3389/fonc.2021.674224] 26. Kim S, Kim YJ, Chung WC (2021) HER-2 positivity is a high risk of recurrence of stage I gastric cancer. The Korean Journal of Internal Medicine, 36(6): 1327. [ DOI:10.3904/kjim.2020.243] 27. Namikawa T, Kawanishi Y, Fujisawa K, Munekage, E, et al. (2018) Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer. Surgery Today, 48(4): 388-394. [ DOI:10.1007/s00595-017-1598-3] 28. Wen Y, Zhu Y, Zhang C, Yang X, et al. (2022) Chronic inflammation, cancer development and immunotherapy. Frontiers in Pharmacology, 13: 1040163. [ DOI:10.3389/fphar.2022.1040163] 29. Choi Y, Kim JW, Nam KH, Han SH, et al. (2017) Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. Gastric Cancer, 20(4): 602-611. [ DOI:10.1007/s10120-016-0642-0] 30. Climent M, Ryan ÉJ, Stakelum Á, Khaw YL, et al. (2019) Systemic inflammatory response predicts oncological outcomes in patients undergoing elective surgery for mismatch repair-deficient colorectal cancer. International Journal of Colorectal Disease, 34(6): 1069-1078. [ DOI:10.1007/s00384-019-03274-6] 31. Knutson KL and Disis ML (2005) Augmenting T helper cell immunity in cancer. Current Drug Targets-Immune, Endocrine & Metabolic Disorders, 5(4): 365-371. [ DOI:10.2174/156800805774913006] 32. Wirsdörfer F and Jendrossek V (2016) The role of lymphocytes in radiotherapy-induced adverse late effects in the lung. Frontiers in Immunology, 7: 591. [ DOI:10.3389/fimmu.2016.00591] 33. Fan JB and Zhang DE (2013) ISG15 regulates IFN-γ immunity in human mycobacterial disease. Cell Research, 23(2): 173-175. [ DOI:10.1038/cr.2012.133] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Huang Y, Liu H, Liang Y, Xu X, Che Z, Lin Y, et al . Prognostic significance of ISG15 and CD3 in gastric cancer: Implications for immune regulation and radiosensitivity. Int J Radiat Res 2026; 24 (2) :545-552 URL: http://ijrr.com/article-1-7077-en.html
|
